Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior

References

• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, et al. , editors. 4th ed. Lyon: IARC Press; 2008. pp 180–182.
   Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640–1645.
   PubMed Web of Science ®Google Scholar
• Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809–819.
   PubMed Web of Science ®Google Scholar
• Tamura K, Sawada H, Izumi Y, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol 2001;67:152–157.
   PubMed Web of Science ®Google Scholar
• Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000;24:665–669.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–111.
   PubMed Web of Science ®Google Scholar
• Duke VM, Gandini D, Sherrington PD, et al. VH gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003;88:1259–1271.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879–2885.
   PubMed Web of Science ®Google Scholar
• Koiso H, Yamane A, Mitsui T, et al. Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. Leuk Res2006;30:272–276.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Y, Zheng W, et al. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491–1498.
   PubMed Web of Science ®Google Scholar
• Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 2008;58:174–182.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Bennett FL, O'Connor SJM, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575–583.
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853–861.
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515–1525.
   PubMed Web of Science ®Google Scholar
• Garand R, Sahota SS, Avet-Loiseau H, et al. IgG-secreting lymphoplasmacytoid leukemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. Br J Haematol 2000;109:71–80.
   PubMed Web of Science ®Google Scholar
• Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotype and genotypic features. Blood 2003;102:1035–1041.
   PubMed Web of Science ®Google Scholar
• Oscier D, Fegan C, Hillmen P, et al. , Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haemotology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004;125:294–317.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679–4685.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135–1144.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• [twb space="3"]Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087–1093.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Dono M, Wakai M, et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+CD5+ chronic lymphocytic leukemia B cells. J Exp Med 1995;181:1507–1517.
   PubMed Web of Science ®Google Scholar
• Potter KN, Mockridge I, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006;12:1672–1679.
   PubMed Web of Science ®Google Scholar
• Scielzo C, Camporeale A, Geuna M, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturation stage. Leukemia 2005;20:689–695.
   Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Thorsélius M, Walsh S, Eriksson I, et al. Somatic hypermutation and VH gene usage in mantle cell lymphoma. Eur J Haematol 2002;68:217–224.
   PubMed Web of Science ®Google Scholar
• [twb space="3"]Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003;101:4042–4046.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454–2460.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2008;27:904–910.
   PubMed Web of Science ®Google Scholar
• Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732–1737.
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood MA, Morris TCM, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006;77:309–317.
   PubMed Web of Science ®Google Scholar